Fluidx submits final PMA module for GPX embolic device

Fluidx Medical Technology submitted the final module of its premarket approval application to the FDA for the GPX Embolic Device on July 24, 2026. The filing adds pivotal trial data for a device the company says could expand treatment options if regulators clear it.

Why it matters: - The PMA filing moves GPX one step closer to potential U.S. approval. - The device is designed to give clinicians a controllable embolic option across a wide range of vessel sizes and clinical uses. - If approved, GPX could become available to a broader clinical community beyond investigational use.

What happened: - Fluidx Medical Technology said it submitted the final module of its PMA to the FDA for the GPX Embolic Device. - The submission was completed on July 24, 2026. - The final module included results from the pivotal IDE clinical trial. - The trial enrolled 114 patients at 18 sites in the U.S., Canada and New Zealand. - More than 40 investigators participated in the study.

The details: - GPX was delivered through more than 20 microcatheter configurations during the trial. - The tested delivery devices ranged from 1.9Fr to 2.8Fr in outer diameter. - The microcatheters ranged from 110 cm to 165 cm in length. - Fluidx said the range demonstrated broad compatibility with commonly used delivery devices. - Earlier PMA modules already reviewed by the FDA covered pre-clinical testing and manufacturing. - The company describes Fluidx as a clinical stage medical device company advancing embolic technologies. - Fluidx's portfolio includes GPX, ULTRA and IMPASS.

Between the lines: - The submission suggests Fluidx is advancing from clinical testing toward a regulatory decision point. - The trial scope across three countries and many device configurations appears aimed at supporting both safety and usability claims. - CEO Libble Ginster said the filing is a significant milestone toward bringing to market a new category of easy to use, controllable embolic gels. - Ginster also said the company received positive feedback during the clinical trial.

What's next: - The FDA will review the full PMA package before deciding whether GPX can be approved for commercial distribution in the U.S. - Fluidx said GPX is not approved or available for commercial distribution in the United States. - The device may not be approved or available for sale or use in other countries. - GPX is currently being used under an Investigational Device Exemption in the U.S., Canada and New Zealand. - More information is available in Fluidx Medical Technology's announcement.